-
平臺編號：bio-68968
-
國際編號：TIB-37?
-
細胞信息： TIMI.4
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
TIMI.4
ATCC Number：TIB-37?
相關(guān)疾?。毫馨土?br /> 細胞形態(tài)：淋巴樣
是否是腫瘤細胞：0
物種來源：小鼠
生長狀態(tài)：懸浮生長
品系：C57BL/6
數(shù)量：大量
運輸方式：凍存運輸
器官來源：胸腺
規(guī)格：0.5mg Designations: TIMI.4
Depositors: ?R Hyman
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus
Morphology:lymphoblast
Source: Strain: C57BL/6
Organ: thymus
Disease: lymphoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Antigen Expression:H-2b; Thy-1.2
Comments:Derived from a radiation leukemia virus induced thymoma.
The line is sensitive to cortisol (0.001 mM) and PHA (0.02 mg/ml).
TL antigen is not expressed.
Tested and found negative for ectromelia virus (mousepox).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 1104: Ralph P. Retention of lymphocyte characteristics by myelomas and theta+-lymphomas: sensitivity to cortisol and phytohemagglutinin. J. Immunol. 110: 1470-1475, 1973. PubMed: 4541304
1129: Hyman R. Studies on surface antigen variants. Isolation of two complementary variants for Thy 1.2. J. Natl. Cancer Inst. 50: 415-422, 1973. PubMed: 4702114
22528: Ralph P, Nakoinz I. Inhibitory effects of lectins and lymphocyte mitogens on murine lymphomas and myelomas. J. Natl. Cancer Inst. 51: 883-890, 1973. PubMed: 4542714
相關(guān)疾?。毫馨土?br /> 細胞形態(tài)：淋巴樣
是否是腫瘤細胞：0
物種來源：小鼠
生長狀態(tài)：懸浮生長
品系：C57BL/6
數(shù)量：大量
運輸方式：凍存運輸
器官來源：胸腺
規(guī)格：0.5mg Designations: TIMI.4
Depositors: ?R Hyman
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus
Morphology:lymphoblast
Source: Strain: C57BL/6
Organ: thymus
Disease: lymphoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Antigen Expression:H-2b; Thy-1.2
Comments:Derived from a radiation leukemia virus induced thymoma.
The line is sensitive to cortisol (0.001 mM) and PHA (0.02 mg/ml).
TL antigen is not expressed.
Tested and found negative for ectromelia virus (mousepox).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 1104: Ralph P. Retention of lymphocyte characteristics by myelomas and theta+-lymphomas: sensitivity to cortisol and phytohemagglutinin. J. Immunol. 110: 1470-1475, 1973. PubMed: 4541304
1129: Hyman R. Studies on surface antigen variants. Isolation of two complementary variants for Thy 1.2. J. Natl. Cancer Inst. 50: 415-422, 1973. PubMed: 4702114
22528: Ralph P, Nakoinz I. Inhibitory effects of lectins and lymphocyte mitogens on murine lymphomas and myelomas. J. Natl. Cancer Inst. 51: 883-890, 1973. PubMed: 4542714
